Choosing a biosimilar
Biosimilars have been approved for use in Canada since 20093, and there are currently 404, or more biosimilars approved or marketed in Canada. All biosimilar manufacturers must independently demonstrate the quality of their product and perform comparative studies to demonstrate highly similar structure, function, efficacy and safety to the reference biologic.3
At Fresenius-Kabi we uphold the same quality standards in developing and producing biosimilars as the originator biologics.
Benefits of biosimilar medicines
Biosimilars facilitate patient access, provide more affordable treatment options, and encourage innovation.1,2
Lower cost
The development of biosimilars can create lower patient costs for treatment, which can lead to:
- Increased uptake of best-value biologics1,2
- Reinvestment of cost savings in the development of new and innovative therapies1
- Improved patient care1
- Additional treatment choices for patients and HCPs1
Encouraging innovation
The development of biosimilars can create a more progressive, competitive environment, encouraging investment in the development of new biologic products.1
This can lead to:
- Innovation among reference product manufacturers1
- Increased uptake of best-value biologics1,2
- Reinvestment of cost savings in the development of new and innovative therapies1
More information about our commitment to biosimilars and the biosimilars we have in development.
References:
1. IMS Institute 2016. Delivering on the potential of biosimilar medicines. p. 3, 6, 8, 10, 29 at: www.medicinesforeurope.com.
2. IMS Health 2016. The impact of biosimilar competition, p. 4, 6 and 7. at: www.medicinesforeurope.com.
3.Health Canada. Biosimilar biologic drugs in Canada: fact sheet. 2019
4.Canadian Biologics Market report for Q2 – 2022